Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.52
MRK's Cash to Debt is ranked lower than
72% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. MRK: 0.52 )
Ranked among companies with meaningful Cash to Debt only.
MRK' s 10-Year Cash to Debt Range
Min: 0.32  Med: 0.73 Max: 2.45
Current: 0.52
0.32
2.45
Equity to Asset 0.44
MRK's Equity to Asset is ranked lower than
76% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. MRK: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
MRK' s 10-Year Equity to Asset Range
Min: 0.34  Med: 0.43 Max: 0.53
Current: 0.44
0.34
0.53
Interest Coverage 7.75
MRK's Interest Coverage is ranked lower than
82% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2065.49 vs. MRK: 7.75 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s 10-Year Interest Coverage Range
Min: 3.31  Med: 20.01 Max: 44.62
Current: 7.75
3.31
44.62
F-Score: 4
Z-Score: 3.29
M-Score: -2.87
WACC vs ROIC
2.29%
6.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.51
MRK's Operating margin (%) is ranked higher than
64% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. MRK: 12.51 )
Ranked among companies with meaningful Operating margin (%) only.
MRK' s 10-Year Operating margin (%) Range
Min: 5.15  Med: 22.79 Max: 43.77
Current: 12.51
5.15
43.77
Net-margin (%) 26.98
MRK's Net-margin (%) is ranked higher than
92% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. MRK: 26.98 )
Ranked among companies with meaningful Net-margin (%) only.
MRK' s 10-Year Net-margin (%) Range
Min: 1.87  Med: 19.58 Max: 47.03
Current: 26.98
1.87
47.03
ROE (%) 23.27
MRK's ROE (%) is ranked higher than
85% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.19 vs. MRK: 23.27 )
Ranked among companies with meaningful ROE (%) only.
MRK' s 10-Year ROE (%) Range
Min: 1.51  Med: 33.15 Max: 48.6
Current: 23.27
1.51
48.6
ROA (%) 10.85
MRK's ROA (%) is ranked higher than
78% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. MRK: 10.85 )
Ranked among companies with meaningful ROA (%) only.
MRK' s 10-Year ROA (%) Range
Min: 0.79  Med: 15.50 Max: 18.45
Current: 10.85
0.79
18.45
ROC (Joel Greenblatt) (%) 98.23
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.97 vs. MRK: 98.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MRK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.88  Med: 66.49 Max: 144.19
Current: 98.23
10.88
144.19
Revenue Growth (3Y)(%) -2.40
MRK's Revenue Growth (3Y)(%) is ranked lower than
75% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. MRK: -2.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRK' s 10-Year Revenue Growth (3Y)(%) Range
Min: -16.5  Med: 3.60 Max: 21.4
Current: -2.4
-16.5
21.4
EBITDA Growth (3Y)(%) 19.10
MRK's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. MRK: 19.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MRK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.6  Med: 3.80 Max: 44.7
Current: 19.1
-17.6
44.7
EPS Growth (3Y)(%) 26.30
MRK's EPS Growth (3Y)(%) is ranked higher than
79% of the 451 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. MRK: 26.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRK' s 10-Year EPS Growth (3Y)(%) Range
Min: -42.7  Med: 6.70 Max: 73.8
Current: 26.3
-42.7
73.8
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MRK Guru Trades in Q3 2014

Stanley Druckenmiller 329,600 sh (New)
Ray Dalio 14,141 sh (New)
Steven Cohen 321,100 sh (+1766.86%)
Joel Greenblatt 536,550 sh (+323.00%)
Paul Tudor Jones 31,725 sh (+139.15%)
Ruane Cunniff 4,784 sh (+3.80%)
Mario Gabelli 162,706 sh (+1.49%)
Robert Bruce 265,000 sh (+1.34%)
Ken Fisher 6,533,475 sh (+1.07%)
Brian Rogers 6,625,700 sh (unchged)
Prem Watsa 12,000 sh (unchged)
RS Investment Management 861,075 sh (unchged)
Pioneer Investments 4,327,974 sh (unchged)
George Soros Sold Out
James Barrow 22,769,088 sh (-0.11%)
NWQ Managers 83,811 sh (-0.59%)
Richard Snow 5,375 sh (-0.65%)
Manning & Napier Advisors, Inc 377,389 sh (-0.74%)
Bill Frels 106,735 sh (-0.75%)
Kahn Brothers 1,109,189 sh (-0.97%)
Jim Simons 787,634 sh (-0.99%)
Tom Russo 4,336 sh (-1.14%)
Vanguard Health Care Fund 33,420,748 sh (-1.38%)
Jeff Auxier 147,484 sh (-1.50%)
Dodge & Cox 35,057,668 sh (-2.51%)
Murray Stahl 46,821 sh (-3.00%)
Charles Brandes 2,320,288 sh (-4.69%)
First Eagle Investment 1,083,826 sh (-38.25%)
Signature Select Canadian Fund 163,400 sh (-45.44%)
Jeremy Grantham 118,890 sh (-65.13%)
» More
Q4 2014

MRK Guru Trades in Q4 2014

PRIMECAP Management 700,000 sh (New)
Joel Greenblatt 1,045,652 sh (+94.88%)
Paul Tudor Jones 53,076 sh (+67.30%)
Ray Dalio 20,541 sh (+45.26%)
Vanguard Health Care Fund 35,788,048 sh (+7.08%)
Manning & Napier Advisors, Inc 399,235 sh (+5.79%)
Ken Fisher 6,640,510 sh (+1.64%)
Bill Frels 107,684 sh (+0.89%)
James Barrow 22,856,934 sh (+0.39%)
NWQ Managers 83,828 sh (+0.02%)
Ruane Cunniff 4,784 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Richard Snow 5,375 sh (unchged)
Tom Russo 4,336 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Stanley Druckenmiller Sold Out
Murray Stahl 46,801 sh (-0.04%)
Jeff Auxier 147,334 sh (-0.10%)
Charles Brandes 2,306,840 sh (-0.58%)
Robert Bruce 259,400 sh (-2.11%)
Steven Cohen 311,600 sh (-2.96%)
Dodge & Cox 33,616,093 sh (-4.11%)
Kahn Brothers 1,052,807 sh (-5.08%)
Mario Gabelli 144,408 sh (-11.25%)
RS Investment Management 674,675 sh (-21.65%)
Pioneer Investments 3,201,729 sh (-26.02%)
Jim Simons 575,624 sh (-26.92%)
Jeremy Grantham 13,022 sh (-89.05%)
First Eagle Investment 9,050 sh (-99.16%)
» More
Q1 2015

MRK Guru Trades in Q1 2015

Jim Simons 1,194,169 sh (+107.46%)
PRIMECAP Management 1,385,000 sh (+97.86%)
Paul Tudor Jones 97,093 sh (+82.93%)
RS Investment Management 898,325 sh (+33.15%)
Vanguard Health Care Fund 40,096,948 sh (+12.04%)
Mario Gabelli 160,943 sh (+11.45%)
James Barrow 24,464,116 sh (+7.03%)
Ken Fisher 6,679,499 sh (+0.59%)
Richard Snow 5,375 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Prem Watsa 12,000 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Ruane Cunniff 4,784 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Ray Dalio Sold Out
Manning & Napier Advisors, Inc 398,354 sh (-0.22%)
Signature Select Canadian Fund 161,300 sh (-1.29%)
Kahn Brothers 1,029,815 sh (-2.18%)
Bill Frels 105,158 sh (-2.35%)
Charles Brandes 2,221,791 sh (-3.69%)
NWQ Managers 76,286 sh (-9.00%)
Tom Russo 3,836 sh (-11.53%)
Murray Stahl 41,051 sh (-12.29%)
Pioneer Investments 2,753,869 sh (-13.99%)
Dodge & Cox 25,448,977 sh (-24.30%)
Jeremy Grantham 8,922 sh (-31.49%)
Joel Greenblatt 676,758 sh (-35.28%)
Jeff Auxier 40,324 sh (-72.63%)
Steven Cohen 77,800 sh (-75.03%)
» More
Q2 2015

MRK Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 6,347,239 sh (+1493.37%)
Vanguard Health Care Fund 45,748,498 sh (+14.09%)
Ken Fisher 6,836,547 sh (+2.35%)
Brian Rogers 6,625,700 sh (unchged)
Kahn Brothers 1,016,613 sh (-1.28%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Merck & Co Inc

Bill Nygren Comments on Merck - Apr 10, 2014

We eliminated our position in Merck (NYSE:MRK) as the shares appreciated to our estimate of fair value.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Merck & Co Inc

Vanguard Adds to Four of Its Largest Stakes
It isn’t surprising that nearly 95% of Vanguard Health Care Fund (Trades, Portfolio)’s holdings are related to health care, drug manufacturing and medical technology. But there has been some jockeying for position within the Fund’s portfolio in the early months of 2015. Read more...
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio
Over the duration of the third quarter the Vanguard Health Care Fund added two new stocks to its holdings. The fund now holds on to 89 stocks valued at $39.18 billion. The following companies are Vanguard's top portfolio holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 15.30
MRK's P/E(ttm) is ranked higher than
83% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.90 vs. MRK: 15.30 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s 10-Year P/E(ttm) Range
Min: 6.67  Med: 17.42 Max: 139.89
Current: 15.3
6.67
139.89
Forward P/E 15.29
MRK's Forward P/E is ranked higher than
77% of the 233 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.27 vs. MRK: 15.29 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 15.30
MRK's PE(NRI) is ranked higher than
83% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.00 vs. MRK: 15.30 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s 10-Year PE(NRI) Range
Min: 6.65  Med: 17.33 Max: 133.39
Current: 15.3
6.65
133.39
P/B 3.49
MRK's P/B is ranked higher than
52% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. MRK: 3.49 )
Ranked among companies with meaningful P/B only.
MRK' s 10-Year P/B Range
Min: 1.72  Med: 3.33 Max: 7.25
Current: 3.49
1.72
7.25
P/S 4.13
MRK's P/S is ranked lower than
55% of the 649 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. MRK: 4.13 )
Ranked among companies with meaningful P/S only.
MRK' s 10-Year P/S Range
Min: 2.01  Med: 3.13 Max: 5.48
Current: 4.13
2.01
5.48
PFCF 31.53
MRK's PFCF is ranked higher than
68% of the 275 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.38 vs. MRK: 31.53 )
Ranked among companies with meaningful PFCF only.
MRK' s 10-Year PFCF Range
Min: 7.8  Med: 14.75 Max: 86.81
Current: 31.53
7.8
86.81
POCF 22.00
MRK's POCF is ranked higher than
66% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.86 vs. MRK: 22.00 )
Ranked among companies with meaningful POCF only.
MRK' s 10-Year POCF Range
Min: 6.33  Med: 12.37 Max: 35.75
Current: 22
6.33
35.75
EV-to-EBIT 10.66
MRK's EV-to-EBIT is ranked higher than
84% of the 486 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.52 vs. MRK: 10.66 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s 10-Year EV-to-EBIT Range
Min: 8.5  Med: 19.05 Max: 104.2
Current: 10.66
8.5
104.2
PEG 3.83
MRK's PEG is ranked lower than
58% of the 251 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.94 vs. MRK: 3.83 )
Ranked among companies with meaningful PEG only.
MRK' s 10-Year PEG Range
Min: 0.54  Med: 3.03 Max: 57.09
Current: 3.83
0.54
57.09
Shiller P/E 22.52
MRK's Shiller P/E is ranked higher than
75% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.83 vs. MRK: 22.52 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s 10-Year Shiller P/E Range
Min: 8.29  Med: 13.89 Max: 25.39
Current: 22.52
8.29
25.39
Current Ratio 1.61
MRK's Current Ratio is ranked lower than
67% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. MRK: 1.61 )
Ranked among companies with meaningful Current Ratio only.
MRK' s 10-Year Current Ratio Range
Min: 1.07  Med: 1.54 Max: 3.7
Current: 1.61
1.07
3.7
Quick Ratio 1.34
MRK's Quick Ratio is ranked lower than
61% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. MRK: 1.34 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s 10-Year Quick Ratio Range
Min: 0.8  Med: 1.20 Max: 3.44
Current: 1.34
0.8
3.44
Days Inventory 130.78
MRK's Days Inventory is ranked lower than
59% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.49 vs. MRK: 130.78 )
Ranked among companies with meaningful Days Inventory only.
MRK' s 10-Year Days Inventory Range
Min: 50.6  Med: 129.85 Max: 332.33
Current: 130.78
50.6
332.33
Days Sales Outstanding 58.81
MRK's Days Sales Outstanding is ranked higher than
60% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.86 vs. MRK: 58.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s 10-Year Days Sales Outstanding Range
Min: 44.42  Med: 56.06 Max: 92.3
Current: 58.81
44.42
92.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.04
MRK's Dividend Yield is ranked higher than
86% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. MRK: 3.04 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s 10-Year Dividend Yield Range
Min: 2.51  Med: 4.09 Max: 6.68
Current: 3.04
2.51
6.68
Dividend Payout 0.46
MRK's Dividend Payout is ranked higher than
70% of the 393 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. MRK: 0.46 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s 10-Year Dividend Payout Range
Min: 0.16  Med: 0.49 Max: 4.22
Current: 0.46
0.16
4.22
Dividend growth (3y) 4.30
MRK's Dividend growth (3y) is ranked lower than
58% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. MRK: 4.30 )
Ranked among companies with meaningful Dividend growth (3y) only.
MRK' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 3.60 Max: 14.8
Current: 4.3
0
14.8
Yield on cost (5-Year) 3.62
MRK's Yield on cost (5-Year) is ranked higher than
82% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. MRK: 3.62 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s 10-Year Yield on cost (5-Year) Range
Min: 3  Med: 4.88 Max: 7.97
Current: 3.62
3
7.97
Share Buyback Rate 1.80
MRK's Share Buyback Rate is ranked higher than
95% of the 463 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.00 vs. MRK: 1.80 )
Ranked among companies with meaningful Share Buyback Rate only.
MRK' s 10-Year Share Buyback Rate Range
Min: 1.8  Med: 1.10 Max: -13
Current: 1.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 42.42
MRK's Price/Tangible Book is ranked lower than
97% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. MRK: 42.42 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s 10-Year Price/Tangible Book Range
Min: 3.19  Med: 12.04 Max: 3735
Current: 42.42
3.19
3735
Price/Projected FCF 1.50
MRK's Price/Projected FCF is ranked higher than
81% of the 321 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. MRK: 1.50 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s 10-Year Price/Projected FCF Range
Min: 0.75  Med: 1.23 Max: 3.04
Current: 1.5
0.75
3.04
Price/DCF (Earnings Based) 2.09
MRK's Price/DCF (Earnings Based) is ranked lower than
57% of the 56 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. MRK: 2.09 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.32
MRK's Price/Median PS Value is ranked higher than
56% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. MRK: 1.32 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s 10-Year Price/Median PS Value Range
Min: 0.68  Med: 1.28 Max: 2.08
Current: 1.32
0.68
2.08
Price/Peter Lynch Fair Value 2.27
MRK's Price/Peter Lynch Fair Value is ranked lower than
52% of the 148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. MRK: 2.27 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MRK' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.57  Med: 1.64 Max: 9.87
Current: 2.27
0.57
9.87
Price/Graham Number 5.29
MRK's Price/Graham Number is ranked lower than
78% of the 366 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. MRK: 5.29 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s 10-Year Price/Graham Number Range
Min: 1.08  Med: 3.37 Max: 36.98
Current: 5.29
1.08
36.98
Earnings Yield (Greenblatt) (%) 9.40
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. MRK: 9.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1  Med: 5.25 Max: 11.8
Current: 9.4
1
11.8
Forward Rate of Return (Yacktman) (%) 11.74
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 308 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.88 vs. MRK: 11.74 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -6.2  Med: 6.00 Max: 22.1
Current: 11.74
-6.2
22.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:MRK.France, MRK.Argentina, 6MK.Germany, MRK.Chile, 0QAH.UK, MRCK34.Brazil, MRK.Switzerland, MRK.Mexico, MRK.Romania,
Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.
» More Articles for MRK

Headlines

Articles On GuruFocus.com
Merck Reports Strong Second Quarter 2015 Earnings with Improved Outlook for the Full Year Jul 31 2015 
Manning & Napier Advisors' Most Weighted Trades in Q2 2015 Jul 10 2015 
Intrexon Corp is expanding his business Jun 25 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Endo International Acquires Par Pharmaceuticals For $8 Billion May 21 2015 
Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 

More From Other Websites
Guinea Plans Ebola Inoculation Campaign After Vaccine Success Aug 01 2015
Guinea Plans Ebola Inoculation Campaign Aug 01 2015
WHO Says Ebola Vaccine Effective in African Trial Jul 31 2015
Ebola game changer? Jul 31 2015
There's more to Merck's Ebola vaccine than money Jul 31 2015
Experimental Ebola vaccine could stop virus in West Africa Jul 31 2015
Experimental Ebola vaccine could stop virus in West Africa Jul 31 2015
Merck: Study shows potential Ebola vaccine has '100 percent efficacy' Jul 31 2015
​Merck should follow GSK’s lead and commit to selling its potential Ebola vaccine at cost Jul 31 2015
Dow 30 Stock Roundup: Pfizer, P&G, Merck Beat on Earnings, DuPont Misses Estimates - Analyst Blog Jul 31 2015
Merck's Ebola Vaccine Found to Be Effective by Expert Panel Jul 31 2015
After Merck success, work goes on with other Ebola vaccines Jul 31 2015
After Merck success, work goes on with other Ebola vaccines Jul 31 2015
CNBC update: Ebola vaccine Jul 31 2015
THLD: Update on 2Q15 Financials Jul 31 2015
Vaccine success holds hope for end to deadly scourge of Ebola Jul 31 2015
Merck's Ebola Vaccine Is 'Highly Effective' Jul 31 2015
Ebola Vaccine 'Highly Effective' Trial Should Continue Jul 31 2015
Merck’s Ebola Vaccine Found to Be Effective by Panel of Experts Jul 31 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK